Nijmegen

• Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Recruiting
  2022-502968-20-02 4 2024-05-30 Behcet's disease
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma
• Metamizole as pain treatment in patients with chronic pancreatitis, a multicenter, randomized, double-blind, placebo-controlled, superiority … Recruiting
  2023-504143-14-00 6 2024-05-02 Chronic pancreatitis
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl … Recruiting
  2022-500031-37-00 5 2024-04-08 ​ stage IA/IIA Hodgkin lymphoma
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa … Recruiting
  2023-503208-94-00 6 2024-04-04 Prostate cancer
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer
• Predicting the effect of blood pressure lowering medication using Multi-Omics, a biomarker profile based on blood and urine analyses Recruiting
  2023-505239-10-00 6 2024-03-19 Primary (essential) hypertension
• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
• PREMI trial Recruiting
  2023-503220-76-01 6 2024-02-13 Unexplained recurrent miscarriages
• A study in men with advanced prostate cancer to determine the safety and effects of a test drug (Lutetium (177Lu) rhPSMA 10.1 injection) Recruiting
  2024-511537-35-00 9 2024-02-09 Metastatic castration-resistant prostate cancer (mCRPC)
• Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting
  2023-504146-60-00 10 2024-02-07 lymphatic malformations associated with PIK3CA mutation
• Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol … Recruiting
  2023-506698-36-00 5 2024-02-02 low-volume metastatic castration-sensitive prostate cancer
• A study to investigate the effect of adding cobicistat to venetoclax and azacitidine in patients with acute myeloid leukemia (AML) who are i … Recruiting
  2023-505379-61-00 4 2024-01-17 Acute Myeloid Leukaemia
• PEHAB II Recruiting
  2023-507466-40-00 6 2024-01-12 Prostate cancer
• Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULC … Recruiting
  2022-502685-25-00 10 2024-01-01 The trial population will consist of patients with LAVC who require pr
• Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in n … Recruiting
  2023-504637-42-01 6 2023-12-21 aortic valve stenosis
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting
  2023-510541-25-00 1 2023-10-09 Relapsed/Refractory B-cell Malignancies
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Recruiting
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A study to look at how safe divarasib is when given on its own or in combination with other anti-cancer therapies, and how well these medici … Recruiting
  2023-507171-22-00 9 2023-06-21 Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
• The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ … Recruiting
  2022-501620-26-00 6 2023-05-15 prosthetic joint infection
• A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refra … Recruiting
  2023-504897-39-00 1 2023-04-13 Advanced or refractory solid tumours (Part 1)
• (SPARROW) Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple’s procedure (SPARROW): a … Recruiting
  2024-510766-16-00 11 2023-03-06 Pancreatoduodenectomy with a high risk for contaminated bile

Showing 265–288 of 570 trials